Lv Yalei, Song Lina, Chang Liang, Liu Yan, Zhang Xiaolin, Wang Yudong, Wang Long, Liu Wei
Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.
J BUON. 2016 Nov-Dec;21(6):1466-1470.
To investigate the antitumor effects of the angiogenesis inhibitor bevacizumab combined with chemotherapy, and the application of in vivo imaging technology of growth of fluorescence-labelled gastric cancer (GC) in nude mice.
Twenty-five nude mice were randomly divided into 5 groups (A-E). Subcutaneous xenograft of human MGC803 cells was transplanted to nude mice, followed by different treatments for the groups, including A (bevacizumab combined with chemotherapy), B (24-h chemotherapy with FP followed by bevacizumab), C (bevacizumab 24-h followed by FP chemotherapy), D (bevacizumab only) and E (normal saline). Then, dynamic variation of tumor growth during 4 weeks was evaluated by calculating the tumor inhibition rate and fluorescence signal strength by in vivo imaging system.
After 28-day treatment, fluorescence signal strength in the groups A-D changed significantly compared with the E (control) group, while tumor inhibition rate in C group was highest (68.42%). Furthermore, on the 4th week, the fluorescence signal value in C group was lowest.
Administration of bevacizumab followed by chemotherapy was more effective therapeutic method for GC. The in vivo imaging could show off dynamic variation of tumors and was a sensitive and objective detection method.
探讨血管生成抑制剂贝伐单抗联合化疗的抗肿瘤作用，以及荧光标记的胃癌（GC）在裸鼠体内生长的体内成像技术的应用。
将25只裸鼠随机分为5组（A - E）。将人MGC803细胞皮下异种移植到裸鼠体内，然后对各组进行不同治疗，包括A组（贝伐单抗联合化疗）、B组（先用FP进行24小时化疗，然后用贝伐单抗）、C组（先用贝伐单抗24小时，然后用FP化疗）、D组（仅用贝伐单抗）和E组（生理盐水）。然后，通过体内成像系统计算肿瘤抑制率和荧光信号强度，评估4周内肿瘤生长的动态变化。
治疗28天后，A - D组的荧光信号强度与E组（对照组）相比有显著变化，而C组的肿瘤抑制率最高（68.42%）。此外，在第4周时，C组的荧光信号值最低。
先给予贝伐单抗然后进行化疗是治疗GC更有效的方法。体内成像可以显示肿瘤的动态变化，是一种敏感且客观的检测方法。
